Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ACTRN12626001219370) titled 'A study of BRD-333 in Healthy Adult Participants' on Oct. 2.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Randomised controlled trial
Masking: Blinded (masking used)
Assignment: Parallel
Type of endpoint: Safety
Primary Sponsor: Birdseye Therapeutics Inc
Condition:
Inflammatory diseases
Autoimmune diseases
Inflammatory diseases
Autoimmune diseases
Inflammatory and Immune System - Other inflammatory or immune system disorders
Inflammatory and Immune System - Autoimmune diseases
Intervention:
Part A Single Ascending Dose (SAD)
Part A will assess the safety, tolerability, pharmac...